Immunoliposomes for the targeted delivery of antitumor drugs

Advanced Drug Delivery Reviews

Volumn 40, Issue 1-2, 1999, Pages 103-127

  Mastrobattista, Enrico ^a   Koning, Gerben A ^a,b   Storm, Gert ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Anticancer agents; Immunoliposomes

Indexed keywords

IMMUNOLOGY; ONCOLOGY;

IMMUNOLIPOSOMES;

CONTROLLED DRUG DELIVERY;

ANTIBODY; ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; CYTARABINE; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; IMMUNOLIPOSOME; LIGAND; MACROGOL; METHOTREXATE; MONOCLONAL ANTIBODY; OLIGONUCLEOTIDE; PRODRUG;

CANCER CHEMOTHERAPY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; DRUG TARGETING; DRUG TRANSPORT; ENCAPSULATION; ENDOTHELIUM CELL; HEAT SENSITIVITY; HUMAN; IMMUNOGENICITY; INTERNALIZATION; LUNG SQUAMOUS CELL CARCINOMA; MEMBRANE FUSION; METASTASIS; NONHUMAN; OVARY CANCER; PERITONEAL CAVITY; PH; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STOMACH CANCER; TUMOR VASCULARIZATION;

EID: 0032851735     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00043-5     Document Type: Article

References (167)

1. Kim S. Liposomes as carriers of cancer chemotherapy. Current status and future prospects. Drugs. 46:1993;618-638.
2. Lasic D.D. Novel applications of liposomes. Trends. Biotechnol. 16:1998;307-321.
3. Storm G., Crommelin D.J.A. Liposomes: quo vadis? Pharm. Sci. Tech. Today. 1:1998;19-31.
4. Dass C.R., Walker T.L., Burton M.A., Decruz E.E. Enhanced anticancer therapy mediated by specialized liposomes. J. Pharm. Pharmacol. 49:1997;972-975.
5. Harasym T.O., Bally M.B., Tardi P. Clearance properties of liposomes involving conjugated proteins for targeting. Adv. Drug. Del. Rev. 32:1998;99-118.
6. Forssen E., Willis M. Ligand-targeted liposomes. Adv. Drug. Del. Rev. 29:1998;249-271.
7. Heath T.D., Bragman K.S., Matthay K.K., Lopez-Straubinger N.G., Papahadjopoulos D. Antibody-directed liposomes: the development of a cell-specific cytotoxic agent. Biochem. Soc. Trans. 12:1984;340-342.
8. Allen T.M., Brandeis E., Hansen C.B., Kao G.Y., Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim. Biophys. Acta. 1237:1995;99-108. [published erratum in Biochim Biophys Acta 1995 Dec 13;1240(2):285].
9. Hansen C.B., Kao G.Y., Moase E.H., Zalipsky S., Allen T.M. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta. 1239:1995;133-144.
10. Maruyama K., Takizawa T., Takahashi N., Tagawa T., Nagaike K., Iwatsuru M. Targeting efficiency of PEG-immunoliposome conjugated antibodies at PEG terminals. Adv. Drug. Del. Rev. 24:1997;235-242.
11. Lee R.J., Low P.S. Folate-targeted liposomes for drug delivery. J. Liposome Res. 7:1997;455-466.
12. Kikuchi A., Sugaya S., Ueda H., Tanaka K., Aramaki Y., Hara T., Arima H., Tsuchiya S., Fuwa T. Efficient gene transfer to EGF receptor overexpressing cancer cells by means of EGF-labeled cationic liposomes. Biochem. Biophys. Res. Commun. 227:1996;666-671.
13. Ishii Y., Aramaki Y., Hara T., Tsuchiya S., Fuwa T. Preparation of EGF labeled liposomes and their uptake by hepatocytes. Biochem. Biophys. Res. Commun. 160:1989;732-736.
14. Gyongyossy-Issa M.I., Muller W., Devine D.V. The covalent coupling of Arg-Gly-Asp-containing peptides to liposomes: purification and biochemical function of the lipopeptide. Arch. Biochem. Biophys. 353:1998;101-108.
15. Oku N., Tokudome Y., Koike C., Nishikawa N., Mori H., Saiki I., Okada S. Liposomal Arg-Gly-Asp analogs effectively inhibit metastatic B16 melanoma colonization in murine lungs. Life Sci. 58:1996;2263-2270.
16. Willis M.C., Collins B., Zhang T., Green L.S., Sebesta D.P., Bell C., Kellogg E., Gill S.C., Magallanez A., Knauer S., Bendele R.A., Gill P.S., Janjic N. Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug. Chem. 9:1998;573-582.
17. Torchilin V.P., Khaw B.A., Smirnov V.N., Haber E. Preservation of antimyosin antibody activity after covalent coupling to liposomes. Biochem. Biophys. Res. Commun. 89:1979;1114-1119.
18. Martin F.J., Hubbell W.L., Papahadjopoulos D. Immunospecific targeting of liposomes to cells: a novel and efficient method for covalent attachment of Fab′ fragments via disulfide bonds. Biochemistry. 20:1981;4229-4238.
19. Martin F.J., Papahadjopoulos D. Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting. J. Biol. Chem. 257:1982;286-288.
20. Jones M.N., Nicholas A.R. The effect of blood serum on the size and stability of phospholipid liposomes. Biochim. Biophys. Acta. 1065:1991;145-152.
21. Schenkman S., Araujo P.S., Dijkman R., Quina F.H., Chaimovich H. Effects of temperature and lipid composition on the serum albumin-induced aggregation and fusion of small unilamellar vesicles. Biochim. Biophys. Acta. 649:1981;633-647.
22. Hernandez-Caselles T., Villalain J., Gomez-Fernandez J.C. Influence of liposome charge and composition on their interaction with human blood serum proteins. Mol. Cell Biochem. 120:1993;119-126.
23. Strejan G.H., Essani K., Surlan D. Naturally occurring antibodies to liposomes. II. Specificity and electrophoretic pattern of rabbit antibodies reacting with sphingomyelin-containing liposomes. J. Immunol. 127:1981;160-165.
24. Szebeni J., Wassef N.M., Rudolph A.S., Alving C.R. Complement activation in human serum by liposome-encapsulated hemoglobin: the role of natural anti-phospholipid antibodies. Biochim. Biophys. Acta. 1285:1996;127-130.
25. Derksen J.T., Morselt H.W., Scherphof G.L. Uptake and processing of immunoglobulin-coated liposomes by subpopulations of rat liver macrophages. Biochim. Biophys. Acta. 971:1988;127-136.
26. Dijkstra J., Van Galen M., Scherphof G. Influence of liposome charge on the association of liposomes with Kupffer cells in vitro. Effects of divalent cations and competition with latex particles. Biochim. Biophys. Acta. 813:1985;287-297.
27. Aragnol D., Leserman L.D. Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc. Natl. Acad. Sci. USA. 83:1986;2699-2703.
28. Wallace P.K., Howell A.L., Fanger M.W. Role of Fc gamma receptors in cancer and infectious disease. J. Leukoc. Biol. 55:1994;816-826.
29. Betageri G.V., Black C.D., Szebeni J., Wahl L.M., Weinstein J.N. Fc-receptor-mediated targeting of antibody-bearing liposomes containing dideoxycytidine triphosphate to human monocyte/macrophages. J. Pharm. Pharmacol. 45:1993;48-53.
30. Torchilin V.P. Polymer-coated long-circulating microparticulate pharmaceuticals. J. Microencapsul. 15:1998;1-19.
31. Storm G., Belliot S.O., Daemen T., Lasic D.D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug. Del. Rev. 17:1995;31-48.
32. Alving C.R., Wassef N.M. Complement-dependent phagocytosis of liposomes: suppression by 'stealth' lipids. J. Liposome Res. 2:1992;383-395.
33. Chonn A., Cullis P.R. Ganglioside GM, and hydrophylic polymers increase liposome circulation times by inhibiting the association of blood proteins. J. Liposome Res. 2:1992;397-410.
34. Blume G., Cevc G., Crommelin D.J.A., Bakker-Woudenberg I.A., Kluft C., Storm G. Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim. Biophys. Acta. 1149:1993;180-184.
35. Huwyler J., Yang J., Pardridge W.M. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. J. Pharmacol. Exp. Ther. 282:1997;1541-1546.
36. Maruyama K., Takahashi N., Tagawa T., Nagaike K., Iwatsuru M. Immunoliposomes bearing polyethyleneglycol-coupled Fab′ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett. 413:1997;177-180.
37. Phillips N.C., Dahman J. Immunogenicity of immunoliposomes: reactivity against species-specific IgG and liposomal phospholipids. Immunol. Lett. 45:1995;149-152.
38. Harding J.A., Engbers C.M., Newman M.S., Goldstein N.I., Zalipsky S. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim. Biophys. Acta. 1327:1997;181-192.
39. Dvorak H.F., Nagy J.A., Dvorak J.T., Dvorak A.M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 133:1988;95-109.
40. Dvorak H.F. Leaky tumor vessels: consequences for tumor stroma generation and for solid tumor therapy. Prog. Clin. Biol. Res. 354A:1990;317-330.
41. Wu N.Z., Braun R.D., Gaber M.H., Lin G.M., Ong E.T., Shan S., Papahadjopoulos D., Dewhirst M.W. Simultaneous measurement of liposome extravasation and content release in tumors. Microcirculation. 4:1997;83-101.
42. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54:1994;3352-3356.
43. Wu N.Z., Da D., Rudoll T.L., Needham D., Whorton A.R., Dewhirst M.W. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res. 53:1993;3765-3770.
44. Huang S.K., Martin F.J., Jay G., Vogel J., Papahadjopoulos D., Friend D.S. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am. J. Pathol. 143:1993;10-14.
45. Brown J.M., Giaccia A.J. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res. 58:1998;1408-1416.
46. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. J. Control. Release. 53:1998;49-67.
47. Mayer L.D., Dougherty G., Harasym T.O., Bally M.B. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. J. Pharmacol. Exp. Ther. 280:1997;1406-1414.
48. Park J.W., Hong K., Kirpotin D.B., Meyer O., Papahadjopoulos D., Benz C.C. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett. 118:1997;153-160.
49. Huang S.K., Lee K.D., Hong K., Friend D.S., Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 52:1992;5135-5143.
50. Scherphof G.L., Kamps J.A.A.M., Koning G.A. In vivo targeting of surface-modified liposomes to metastatically growing colon carcinoma cells and sinusoidal endothelial cells in the rat liver. J. Liposome Res. 7:1997;419-432.
51. Kirpotin D.B., Park J.W., Hong K., Shao Y., Colbern G., Zheng W.W., Meyer O., Benz C.C., Papahadjopoulos D. Targeting of sterically stabilized liposomes to cancers overexpressing her2/neu proto-oncogene. Lasic D.D., Papahadjopoulos D. Medical Applications of Liposomes. 1998;325-345 Elsevier, Amsterdam.
52. Weinstein J.N., Eger R.R., Covell D.G., Black C.D., Mulshine J., Carrasquillo J.A., Larson S.M., Keenan A.M. The pharmacology of monoclonal antibodies. Ann. NY Acad. Sci. 507:1987;199-210.
53. Allen T.M., Ahmad I., Lopes de Menezes D.E., Moase E.H. Immunoliposome-mediated targeting of anti-cancer drugs in vivo. Biochem. Soc. Trans. 23:1995;1073-1079.
54. Allen T.M. Liposome targeting in animal models: problems and opportunities. J. Liposome Res. 7:1997;315-329.
55. Sedmak D.D., Davis D.H., Singh U., van de Winkel J.G., Anderson C.L. Expression of IgG Fc receptor antigens in placenta and on endothelial cells in humans. An immunohistochemical study, Am. J. Pathol. 138:1991;175-181.
56. Bengualid V., Hatcher V.B., Diamond B., Blumberg E.A., Lowy F.D. Staphylococcus aureus infection of human endothelial cells potentiates Fc receptor expression. J. Immunol. 145:1990;4279-4283.
57. Holland J.W., Hui C., Cullis P.R., Madden T.D. Poly(ethylene glycol)-lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine. Biochemistry. 35:1996;2618-2624.
58. Suzuki S., Watanabe S., Masuko T., Hashimoto Y. Preparation of long-circulating immunoliposomes containing adriamycin by a novel method to coat immunoliposomes with poly(ethylene glycol). Biochim. Biophys. Acta. 1245:1995;9-16.
59. Kirpotin D., Park J.W., Hong K., Zalipsky S., Li W.L., Carter P., Benz C.C., Papahadjopoulos D. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry. 36:1997;66-75.
60. Maruyama K., Mori A., Bhadra S., Subbiah M.T., Huang L. Proteins and peptides bound to long-circulating liposomes. Biochim. Biophys. Acta. 1070:1991;246-252.
61. Mori A., Klibanov A.L., Torchilin V.P., Huang L. Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett. 284:1991;263-266.
62. Klibanov A.L., Maruyama K., Beckerleg A.M., Torchilin V.P., Huang L. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim. Biophys. Acta. 1062:1991;142-148.
63. Torchilin V.P., Narula J., Halpern E., Khaw B.A. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. Biochim. Biophys. Acta. 1279:1996;75-83.
64. Maruyama K., Takizawa T., Yuda T., Kennel S.J., Huang L., Iwatsuru M. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim. Biophys. Acta. 1234:1995;74-80.
65. Hansen C.B., Kao G.Y., Moase E.H., Zalipsky S., Allen T.M. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta. 1239:1995;133-144.
66. Allen T.M., Hansen C.B., Stuart D.D. Targeted sterically stabilized liposomal drug delivery. Lasic D.D., Papahadjopoulos D. Medical Applications of Liposomes. 1998;297-323 Elsevier, Amsterdam.
67. Thierry A.R., Vige D., Coughlin S.S., Belli J.A., Dritschilo A., Rahman A. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J. 7:1993;572-579.
68. Sadasivan R., Morgan R., Fabian C., Stephens R. Reversal of multidrug resistance in HL-60 cells by verapamil and liposome-encapsulated doxorubicin. Cancer Lett. 57:1991;165-171.
69. Thierry A.R., Jorgensen T.J., Forst D., Belli J.A., Dritschilo A., Rahman A. Modulation of multidrug resistance in Chinese hamster cells by liposome-encapsulated doxorubicin. Cancer Commun. 1:1989;311-316. [published erratum appears in Cancer Commun 1989 Dec;1(6):395].
70. Lopes de Menezes D.E., Pilarski L.M., Allen T.M. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 58:1998;3320-3330.
71. Kirpotin D., Hong K., Mullah N., Papahadjopoulos D., Zalipsky S. Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). FEBS Lett. 388:1996;115-118.
72. Pinnaduwage P., Huang L. Stable target-sensitive immunoliposomes. Biochemistry. 31:1992;2850-2855.
73. Gaber M.H., Wu N.Z., Hong K., Huang S.K., Dewhirst M.W., Papahadjopoulos D. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int. J. Radiat. Oncol. Biol. Phys. 36:1996;1177-1187.
74. van Bree C., Krooshoop J.J., Rietbroek R.C., Kipp J.B., Bakker P.J. Hyperthermia enhances tumor uptake and antitumor efficacy of thermostable liposomal daunorubicin in a rat solid tumor. Cancer Res. 56:1996;563-568.
75. Yatvin M.B., Tegmo-Larsson I.M., Dennis W.H. Temperature-and pH-sensitive liposomes for drug targeting. Methods Enzymol. 149:1987;77-87.
76. Sullivan S.M., Huang L. Enhanced delivery to target cells by heat-sensitive immunoliposomes. Proc. Natl. Acad. Sci. USA. 83:1986;6117-6121.
77. Huang L., Connor J., Wang C.Y. pH-sensitive immunoliposomes. Methods Enzymol. 149:1987;88-99.
78. Bennett D.E., Lamparski H., O'Brien D.F. Photosensitive liposomes. J. Liposome Res. 4:1994;331-348.
79. Morgan J., MacRobert A.J., Gray A.G., Huehns E.R. Use of photosensitive, antibody directed liposomes to destroy target populations of cells in bone marrow: a potential purging method for autologous bone marrow transplantation. Br. J. Cancer. 65:1992;58-64.
80. Khoobehi B., Char C.A., Peyman G.A., Schuele K.M. Study of the mechanisms of laser-induced release of liposome-encapsulated dye. Lasers. Surg. Med. 10:1990;303-309.
81. Schwendener R.A., Schott H. Lipophilic 1-β-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model. J. Cancer Res. Clin. Oncol. 122:1996;723-726.
82. Sasaki H., Kakutani T., Hashida M., Sezaki H. Characterization of alkylcarbamoyl derivatives of 5-fluorouracil and their application to liposome. Int. J. Pharm. 36:1987;147-156.
83. Schwendener R.A., Supersaxo A., Rubas W., Weder H.G., Hartmann H.R., Schott H., Ziegler A., Hengartner H. 5′-O-Palmitoyl- and 3′,5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine-novel lipophilic analogues of 5′-fluoro-2′-deoxyuridine: synthesis, incorporation into liposomes and preliminary biological results. Biochem. Biophys. Res. Commun. 126:1985;660-666.
84. van Borssum Waalkes M., Van Galen M., Morselt H.W.M., Sternberg B., Scherphof G.L. In vitro stability and cytostatic activity of liposomal formulations of 5-fluoro-2′-deoxyuridine and its diacylated derivatives. Biochim. Biophys. Acta. 1148:1993;161-172.
85. Kinsky S.C., Loader J.E. Circumvention of the methotrexate transport system by methotrexate-phosphatidylethanolamine derivatives: effect of fatty acid chain length. Biochim. Biophys. Acta. 921:1987;96-103.
86. Mori A., Kennel S.J., van Borssum Waalkes M., Scherphof G.L., Huang L. Characterization of organ-specific immunoliposomes for delivery of 3′,5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine in a mouse lung-metastasis model. Cancer Chemother. Pharmacol. 35:1995;447-456.
87. Crosasso P., Brusa P., Dosio F., Arpicco S., Pacchioni D., Schuber F., Cattel L. Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs. J. Pharm. Sci. 86:1997;832-839.
88. G.A. Koning, A. Gorter, G.L. Scherphof, J.A.A.M. Kamps, Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells, Br. J. Cancer (1999), in press.
89. van Borssum Waalkes M., Fichtner I., Dontje B., Lemm M., Becker M., Arndt D., Scherphof G.L. In vivo distribution and antitumour activity of liposomal 3′,5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine. J. Microencapsul. 9:1992;335-346.
90. G.A. Koning, H.W. M. Morselt, M.J. Velinova, J. Donga, A. Gorter, T.M. Allen, S. Zalipsky, J.A.A.M. Kamps, G.L. Scherphof, Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine (FUdR) from immunoliposomes to CC531 colon cancer cells, Biochim. Biophys. Acta (1999), submitted for publication.
91. Sarti P., Ginobbi P., D'Agostino I., Arancia G., Lendaro E., Molinari A., Ippoliti R., Citro G. Liposomal targeting of leukaemia HL60 cells induced by transferrin-receptor endocytosis. Biotechnol. Appl. Biochem. 24:1996;269-276.
92. Lee R.J., Wang S., Turk M.J., Low P.S. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery. Biosci. Rep. 18:1998;69-78.
93. Storm G., Regts J., Beynen F.J., Roerdink F.H. Processing of doxorubicin-containing liposomes by liver macrophages in vitro. J. Liposome Res. 1:1989;195-210.
94. Straubinger R.M., Hong K., Friend D.S., Papahadjopoulos D. Endocytosis of liposomes and intracellular fate of encapsulated molecules: encounter with a low pH compartment after internalization in coated vesicles. Cell. 32:1983;1069-1079.
95. Slepushkin V.A., Simoes S., Dazin P., Newman M.S., Guo L.S., Pedroso de Lima M.C., Duzgunes N. Sterically stabilized pH-sensitive liposomes. Intracellular delivery of aqueous contents and prolonged circulation in vivo. J. Biol. Chem. 272:1997;2382-2388.
96. Connor J., Yatvin M.B., Huang L. pH-sensitive liposomes: acid-induced liposome fusion. Proc. Natl. Acad. Sci. USA. 81:1984;1715-1718.
97. Wang C.Y., Huang L. pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse. Proc. Natl. Acad. Sci. USA. 84:1987;7851-7855.
98. Lutwyche P., Cordeiro C., Wiseman D.J., St-Louis M., Uh M., Hope M.J., Webb M.S., Finlay B.B. Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes. Antimicrob. Agents Chemother. 42:1998;2511-2520.
99. Kono K., Igawa T., Takagishi T. Cytoplasmic delivery of calcein mediated by liposomes modified with a pH-sensitive poly(ethylene glycol) derivative. Biochim. Biophys. Acta. 1325:1997;143-154.
100. Plank C., Zauner W., Wagner E. Application of membrane-active peptides for drug and gene delivery across cellular membranes. Adv. Drug Del. Rev. 34:1998;21-35.
101. Subbarao N.K., Parente R.A., Szoka F.C.J., Nadasdi L., Pongracz K. pH-dependent bilayer destabilization by an amphipathic peptide. Biochemistry. 26:1987;2964-2972.
102. Puyal C., Maurin L., Miquel G., Bienvenue A., Philippot J. Design of a short membrane-destabilizing peptide covalently bound to liposomes. Biochim. Biophys. Acta. 1195:1994;259-266.
103. Pecheur E.I., Hoekstra D., Sainte-Marie J., Maurin L., Bienvenue A., Philippot J.R. Membrane anchorage brings about fusogenic properties in a short synthetic peptide. Biochemistry. 36:1997;3773-3781.
104. Pecheur E.I., Martin I., Ruysschaert J.M., Bienvenue A., Hoekstra D. Membrane fusion induced by 11-mer anionic and cationic peptides: a structure-function study. Biochemistry. 37:1998;2361-2371.
105. Tseng Y.L., Hong R.L., Tao M.H., Chang F.H. Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int. J. Cancer. 80:1999;723-730.
106. Peeters P.A., Oussoren C., Eling W.M., Crommelin D.J. Immunospecific targeting of immunoliposomes, F(ab′)2 and IgG to red blood cells in vivo. Biochim. Biophys. Acta. 943:1988;137-147.
107. Peeters P.A., Claessens C.A., Eling W.M., Crommelin D.J. Immunospecific targeting of liposomes to erythrocytes. Biochem. Pharmacol. 37:1988;2215-2222.
108. Bankert R.B., Yokota S., Ghosh S.K., Mayhew E., Jou Y.H. Immunospecific targeting of cytosine arabinonucleoside-containing liposomes to the idiotype on the surface of a murine B-cell tumor in vitro and in vivo. Cancer Res. 49:1989;301-308.
109. Maruyama K. Long-circulating immunoliposome targeting in animal models. J. Liposome Res. 7:1997;363-389.
110. Vingerhoeds M.H., Steerenberg P.A., Hendriks J.J., Dekker L.C., Van Hoesel Q.G., Crommelin D.J.A., Storm G. Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo. Br. J. Cancer. 74:1996;1023-1029.
111. Straubinger R.M., Lopez N.G., Debs R.J., Hong K., Papahadjopoulos D. Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes. Cancer Res. 48:1988;5237-5245.
112. Nassander U.K., Steerenberg P.A., Poppe H., Storm G., Poels L.G., De Jong W.H., Crommelin D.J.A. In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice. Cancer Res. 52:1992;646-653.
113. Torchilin V.P. Liposomes as targetable drug carriers. Crit. Rev. Ther. Drug Carrier Syst. 2:1985;65-115.
114. Ahmad I., Longenecker M., Samuel J., Allen T.M. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. 53:1993;1484-1488.
115. Kirpotin D.B., Park J.W., Hong K., Zalipsky S., Li W.L., Carter P., Benz C.C., Papahadjopoulos D. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry. 36:1997;66-75.
116. Park J.W., Hong K., Carter P., Asgari H., Guo L.Y., Keller G.A., Wirth C., Shalaby R., Kotts C., Wood W.I. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA. 92:1995;1327-1331.
117. Goren D., Horowitz A.T., Zalipsky S., Woodle M.C., Yarden Y., Gabizon A. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br. J. Cancer. 74:1996;1749-1756.
118. Maruyama K., Takahashi N., Tagawa T., Nagaike K., Iwatsuru M. Immunoliposomes bearing polyethyleneglycol-coupled Fab′ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett. 413:1997;177-180.
119. Frodin J.E., Lefvert A.K., Mellstedt H. The clinical significance of HAMA in patients treated with mouse monoclonal antibodies. Cell Biophys. 21:1992;153-165.
120. Gorman S.D., Clark M.R. Humanisation of monoclonal antibodies for therapy. Semin. Immunol. 2:1990;457-466.
121. Winter G., Harris W.J. Humanized antibodies. Immunol. Today. 14:1993;243-246.
122. Lonberg N., Huszar D. Human antibodies from transgenic mice. Int. Rev. Immunol. 13:1995;65-93.
123. Jakobovits A. Production of fully human antibodies by transgenic mice. Curr. Opin. Biotechnol. 6:1995;561-566.
124. Laukkanen M.L., Alfthan K., Keinanen K. Functional immunoliposomes harboring a biosynthetically lipid-tagged single-chain antibody. Biochemistry. 33:1994;11664-11670.
125. de Kruif J., Storm G., van Bloois L., Logtenberg T. Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes. FEBS Lett. 399:1996;232-236.
126. Klug S.J., Famulok M. All you wanted to know about SELEX. Mol. Biol. Rep. 20:1994;97-107.
127. Gold L., Brown D., He Y., Shtatland T., Singer B.S., Wu Y. From oligonucleotide shapes to genomic SELEX: novel biological regulatory loops. Proc. Natl. Acad. Sci. USA. 94:1997;59-64.
128. Tuerk C. Using the SELEX combinatorial chemistry process to find high affinity nucleic acid ligands to target molecules. Methods Mol. Biol. 67:1997;219-230.
129. Wang S., Low P.S. Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells. J. Control. Release. 53:1998;39-48.
130. Lee R.J., Low P.S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 269:1994;3198-3204.
131. Lee R.J., Low P.S. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta. 1233:1995;134-144.
132. Chelvi T.P., Ralhan R. Designing of thermosensitive liposomes from natural lipids for multimodality cancer therapy. Int. J. Hyperthermia. 11:1995;685-695.
133. Yatvin M.B., Cree T.C., Tegmo-Larsson I.M., Gipp J.J. Liposomes as drug carriers in cancer therapy: hyperthermia and pH sensitivity as modalities for targeting. Strahlentherapie. 160:1984;732-740.
134. Chelvi T.P., Jain S.K., Ralhan R. Hyperthermia-mediated targeted delivery of thermosensitive liposome-encapsulated melphalan in murine tumors. Oncol. Res. 7:1995;393-398.
135. Sharma D., Chelvi T.P., Kaur J., Ralhan R. Thermosensitive liposomal taxol formulation: heat-mediated targeted drug delivery in murine melanoma. Melanoma Res. 8:1998;240-244.
136. Connor J., Yatvin M.B., Huang L. pH-sensitive liposomes: acid-induced liposome fusion. Proc. Natl. Acad. Sci. USA. 81:1984;1715-1718.
137. Collins D., Huang L. Cytotoxicity of diphtheria toxin A fragment to toxin-resistant murine cells delivered by pH-sensitive immunoliposomes. Cancer Res. 47:1987;735-739.
138. Connor J., Huang L. pH-sensitive immunoliposomes as an efficient and target-specific carrier for antitumor drugs. Cancer Res. 46:1986;3431-3435.
139. Connor J., Norley N., Huang L. Biodistribution of pH-sensitive immunoliposomes. Biochim. Biophys. Acta. 884:1986;474-481.
140. Slepushkin V.A., Simoes S., Dazin P., Newman M.S., Guo L.S., Pedroso d.L.M., Duzgunes N. Sterically stabilized pH-sensitive liposomes. Intracellular delivery of aqueous contents and prolonged circulation in vivo. J. Biol. Chem. 272:1997;2382-2388.
141. Subbarao N.K., Parente R.A., Szoka F.C.J., Nadasdi L., Pongracz K. pH-dependent bilayer destabilization by an amphipathic peptide. Biochemistry. 26:1987;2964-2972.
142. Nieva J.L., Nir S., Muga A., Goni F.M., Wilschut J. Interaction of the HIV-1 fusion peptide with phospholipid vesicles: different structural requirements for fusion and leakage. Biochemistry. 33:1994;3201-3209.
143. 2-terminal domain of the HIV2 gp41. FEBS Lett. 405:1997;351-355.
144. Pecheur E.I., Martin I., Ruysschaert J.M., Bienvenue A., Hoekstra D. Membrane fusion induced by 11-mer anionic and cationic peptides: a structure-function study. Biochemistry. 37:1998;2361-2371.
145. Bailey A.L., Monck M.A., Cullis P.R. pH-induced destabilization of lipid bilayers by a lipopeptide derived from influenza hemagglutinin. Biochim. Biophys. Acta. 1324:1997;232-244.
146. Mechtler K., Wagner E. Gene transfer mediated by influenza virus peptides: the role of peptide sequences. New J. Chem. 21:1997;105-111.
147. Plank C., Oberhauser B., Mechtler K., Koch C., Wagner E. The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. J. Biol. Chem. 269:1994;12918-12924.
148. Singhal A., Gupta C.M. Antibody-mediated targeting of liposomes to red cells in vivo. FEBS Lett. 201:1986;321-326.
149. Bailey A.L. Antibody-directed enzyme prodrug therapy (Adept). J. Control. Release. 28:1994;187-193.
150. Vingerhoeds M.H., Haisma H.J., van Muijen M., van de Rijt R.B., Crommelin D.J.A., Storm G. A new application for liposomes in cancer therapy. Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs. FEBS Lett. 336:1993;485-490.
151. H.J. Haisma, E. Boven, M. van Muijen, J. de Jong, W.J. van der Vijgh, H.M. Pinedo, A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer, Br. J. Cancer 66 (1992) 474-478.
152. Vingerhoeds M.H., Haisma H.J., Belliot S.O., Smit R.H., Crommelin D.J.A., Storm G. Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity. Pharm. Res. 13:1996;604-610.
153. Bally M.B., Lim H., Cullis P.R., Mayer L.D. Controlling the drug delivery attributes of lipid-based drug formulations. J. Liposome Res. 8:1998;299-335.
154. Pak C.C., Ali S., Janoff A.S., Meers P. Triggerable liposomal fusion by enzyme cleavage of a novel peptide-lipid conjugate. Biochim. Biophys. Acta. 1372:1998;13-27.
155. Brekken R.A., Huang X., King S.W., Thorpe P.E. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res. 58:1998;1952-1959.
156. Molema G., Griffioen A.W. Rocking the foundations of solid tumor growth by attacking the tumor's blood supply. Immunol. Today. 19:1998;392-394.
157. Burrows F.J., Thorpe P.E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl. Acad. Sci. USA. 90:1993;8996-9000.
158. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:1998;377-380.
159. Huang X., Molema G., King S., Watkins L., Edgington T.S., Thorpe P.E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 275:1997;547-550.
160. Bendas G., Krause A., Schmidt R., Vogel J., Rothe U. Selectins as new targets for immunoliposome-mediated drug delivery. A potential way of anti-inflammatory therapy. Pharm. Acta Helv. 73:1998;19-26.
161. Bloemen P.G.M., Henricks P.A.J., van Bloois L., van den Tweel M.C., Bloem A.C., Nijkamp F.P., Crommelin D.J.A., Storm G. Adhesion molecules: a new target for immunoliposome-mediated drug delivery. FEBS Lett. 357:1995;140-144.
162. Mastrobattista, E., Storm, G., van Bloois, L., Reszka, R., Bloemen, P.G.M., Crommelin, D.J.A., Henricks, P.A. J. Cellular uptake of liposomes targeted to intercellular adhesion molecule-1 (ICAM-1) on bronchial epithelial cells. Biochim. Biophys. Acta (1999), in press.
163. Spragg D.D., Alford D.R., Greferath R., Larsen C.E., Lee K.D., Gurtner G.C., Cybulsky M.I., Tosi P.F., Nicolau C., Gimbrone M.A. Jr. Immunotargeting of liposomes to activated vascular endothelial cells: A strategy for site-selective delivery in the cardiovascular system. Proc. Natl. Acad. Sci. USA. 94:1997;8795-8800.
164. Kamps J.A., Morselt H.W., Swart P.J., Meijer D.K., Scherphof G.L. Massive targeting of liposomes, surface-modified with anionized albumins, to hepatic endothelial cells. Proc. Natl. Acad. Sci. USA. 94:1998;11681-11685.
165. Maruyama K., Takizawa T., Yuda T., Kennel S.J., Huang L., Iwatsuru M. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim. Biophys. Acta. 1234:1995;74-80.
166. Zalipsky S., Hansen C.B., Lopes de Menezes D.E., Allen T.M. Long-circulating, polyethylene glycol-grafted immunoliposomes. J. Control. Release. 39:1996;153-161.
167. Schnitzer J.E. Vascular targeting as a strategy for cancer therapy. New Engl. J. Med. 339:1998;472-474.